These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2935970

  • 1. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F, Xhonneux B, Tollenaere JP, Janssen PA.
    Thromb Res; 1985 Dec 01; 40(5):581-96. PubMed ID: 2935970
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F, David JL, Janssen PA.
    Agents Actions; 1982 Jul 01; 12(3):388-97. PubMed ID: 6215842
    [Abstract] [Full Text] [Related]

  • 3. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
    De Clerck F, Xhonneux B, Leysen J, Janssen PA.
    Thromb Res; 1984 Feb 01; 33(3):305-21. PubMed ID: 6710435
    [Abstract] [Full Text] [Related]

  • 4. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F, Xhonneux B.
    Agents Actions; 1986 Mar 01; 17(5-6):515-26. PubMed ID: 2939698
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F, Xhonneux B.
    J Cardiovasc Pharmacol; 1985 Mar 01; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [Abstract] [Full Text] [Related]

  • 7. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J, Heptinstall S.
    Thromb Res; 1983 Jun 01; 30(5):415-23. PubMed ID: 6612677
    [Abstract] [Full Text] [Related]

  • 8. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR.
    J Pharmacol Exp Ther; 1987 Feb 01; 240(2):674-82. PubMed ID: 3806419
    [Abstract] [Full Text] [Related]

  • 9. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J, Leempoels J, Demoen B, Roels V, Verhaegen H.
    J Cardiovasc Pharmacol; 1985 Feb 01; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [Abstract] [Full Text] [Related]

  • 10. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
    Ogawa T, Sugidachi A, Asai F, Koike H.
    Blood Coagul Fibrinolysis; 1998 Apr 01; 9(3):233-40. PubMed ID: 9663705
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
    Killam AL, Cohen ML.
    Thromb Res; 1991 Nov 01; 64(3):331-40. PubMed ID: 1805448
    [Abstract] [Full Text] [Related]

  • 13. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W, Gambino MC, De Gaetano G.
    Eur J Pharmacol; 1984 Aug 17; 103(3-4):261-8. PubMed ID: 6237923
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Further analysis of the inhibitory effects of dihydroergotamine, cyproheptadine and ketanserin on the responses of the rat aorta to 5-hydroxytryptamine.
    Doggrell SA.
    J Auton Pharmacol; 1992 Aug 17; 12(4):223-36. PubMed ID: 1512277
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA, Mann JJ, Nimchinsky E, Cohen ML.
    Life Sci; 1990 Aug 17; 47(23):2089-95. PubMed ID: 2125095
    [Abstract] [Full Text] [Related]

  • 18. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
    Barrett RJ, Appell KC, Kilpatrick BF, Proakis AG, Nolan JC, Walsh DA.
    J Cardiovasc Pharmacol; 1991 Jan 17; 17(1):41-53. PubMed ID: 1708055
    [Abstract] [Full Text] [Related]

  • 19. Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
    Arnout J, van Russelt M, Deckmyn H, Vermylen J.
    Haemostasis; 1987 Jan 17; 17(6):344-8. PubMed ID: 3428721
    [Abstract] [Full Text] [Related]

  • 20. Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
    McLennan PL, Taylor DA.
    Eur J Pharmacol; 1984 Sep 17; 104(3-4):313-8. PubMed ID: 6499925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.